1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

MGI Tech and SeqOne Collaborate to Advance Complete Genomic Analysis

18 Jun 2024
Admin
News Article

MGI Tech and SeqOne Collaborate to Advance Complete Genomic Analysis

Overview

MGI Tech Co., Ltd. and its affiliates have announced a collaboration with SeqOne, a leader in AI-driven genomic decision support software. This partnership is focused on creating and validating comprehensive genomic analysis solutions designed specifically for Human Genetics and Pathology laboratories globally.

The collaboration will focus on three primary projects:

Validation of an Automated HRD Testing Solution: This project will include a joint effort with Agilent Technologies and a Pathology Reference Lab in Spain to validate a cost-effective, automated workflow.

This workflow will utilize Agilent panels, Magnis library preparation automation, MGI’s DNBSEQ-G99 sequencing platform, and SeqOne’s validated HRD signature solution on 96 samples.

The goal is to provide a high-quality, efficient, and adaptable solution for HRD testing, including genomic instability scores and BRCA testing.

Integration of SeqOne’s Analysis Platform with MGI’s MegaBOLT: The collaboration will work on ensuring that SeqOne’s tertiary analysis platform is compatible with MGI’s MegaBOLT, a bioinformatics analysis accelerator developed by MGI.

This integration aims to offer a seamless, cost-effective, and intuitive solution from sample collection to final reporting, particularly suited for high-throughput Human Genetics labs.

Validation of SeqOne’s CE-IVD Platform for Clinical Use: This initiative will evaluate the compatibility of SeqOne’s CE-IVD Platform with MGI sequencers, focusing on variant calling performance with a set of reference control samples in terms of quality control, sensitivity, and precision.

MGI Europe and Africa on Collaboration

• MGI Europe and Africa, expressed enthusiasm about the collaboration, stating, "Combining MGI's advanced sequencing technologies with SeqOne's innovative genomic analysis platform allows us to provide significant insights and solutions for personalized healthcare. This partnership underscores our commitment to advancing genomic research and providing clinicians with the tools necessary for customized patient care."

From SeqOne

SeqOne, remarked, "Our partnership with MGI supports SeqOne’s mission to enhance access to advanced genomic analysis, aiming to improve healthcare outcomes. Integrating SeqOne’s CE-IVD Platform with MGI's technologies will enhance the quality, sensitivity, and precision of bioinformatic analyses."
Together, MGI and SeqOne aim to revolutionize genomic diagnostics, offering innovative solutions to laboratories worldwide.

MGI Tech and SeqOne Collaborate to Advance Complete Genomic Analysis

Overview

The collaboration will focus on three primary projects:

MGI Europe and Africa on Collaboration

From SeqOne

Cookies & Privacy

Select cookies to accept